Search

Search bills, members, committees and pages...

APOTEX CORP.

23 federal lobbying filings, 2023 to 2026.

APOTEX CORP. is a client on 23 federal lobbying filings, 2023 to 2026, reporting $600K across them. Pharmaceutical manufacturer Based in Florida.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.


Firms

2 it has hired, by filings.

RegistrantFilingsReported
APOTEX CORP.15
BALLARD PARTNERS8$600K

By year

Filings and what they reported, newest year first.

YearFilingsIncomeExpenses
20262$1.5M
20259$560K$1.7M
20247$40K$680K
20235$1.4M

Issues

The LDA issue codes the filings were filed under.

CodeIssueFilings
MANManufacturing23
HCRHealth Issues12
TARTariff (miscellaneous tariff bills)4
CPTCopyright/Patent/Trademark2
TRDTrade (domestic/foreign)2

Bills

The bills the filings name, by how many name them.

BillTitleFilings
S. 43Skinny Labels, Big Savings Act4
H.R. 1483Protecting Investors’ Personally Identifiable Information Act2
H.R. 6485Skinny Labels, Big Savings Act2
S. 1302Increasing Transparency in Generic Drug Applications Act2
H.R. 3269ETHIC Act1
H.R. 5526Biosimilar Red Tape Elimination Act1
S. 1954Biosimilar Red Tape Elimination Act1
S. 2276ETHIC Act1
S. 2296National Defense Authorization Act for Fiscal Year 20261
S.J.Res. 37A joint resolution terminating the national emergency declared to impose duties on articles imported from Can…1

Lobbyists

Named on the filings.

LobbyistClientsFilings
STEVEN GIULI115
BRIAN BALLARD18
HUNTER MORGEN18

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

ClientRegistrantPeriodReportedPosted
APOTEX CORP.APOTEX CORP.2026 second_quarter$730KJul 20, 2026
APOTEX CORP.APOTEX CORP.2026 first_quarter$730KApr 20, 2026
APOTEX CORP.BALLARD PARTNERS2025 fourth_quarter$80KJan 20, 2026
APOTEX CORP.APOTEX CORP.2025 fourth_quarter$260KJan 19, 2026
APOTEX CORP.APOTEX CORP.2025 third_quarter$310KOct 17, 2025
APOTEX CORP.BALLARD PARTNERS2025 third_quarter$120KOct 15, 2025
APOTEX CORP.APOTEX CORP.2025 second_quarter$300KJul 18, 2025
APOTEX CORP.BALLARD PARTNERS2025 second_quarter$120KJul 14, 2025
APOTEX CORP.APOTEX CORP.2025 first_quarter$810KApr 21, 2025
APOTEX CORP.BALLARD PARTNERS2025 first_quarter$120KApr 19, 2025
APOTEX CORP.BALLARD PARTNERS2025 first_quarter$120KApr 15, 2025
APOTEX CORP.APOTEX CORP.2024 fourth_quarter$220KJan 20, 2025
APOTEX CORP.BALLARD PARTNERS2024 fourth_quarter$40KJan 18, 2025
APOTEX CORP.BALLARD PARTNERS2024 fourth_quarterJan 1, 2025
APOTEX CORP.BALLARD PARTNERS2024 fourth_quarterDec 17, 2024
APOTEX CORP.APOTEX CORP.2024 third_quarter$160KOct 21, 2024
APOTEX CORP.APOTEX CORP.2024 second_quarter$160KJul 19, 2024
APOTEX CORP.APOTEX CORP.2024 first_quarter$140KApr 19, 2024
APOTEX CORP.APOTEX CORP.2023 fourth_quarter$530KJan 22, 2024
APOTEX CORP.APOTEX CORP.2023 fourth_quarter$530KJan 22, 2024
APOTEX CORP.APOTEX CORP.2023 third_quarter$120KOct 17, 2023
APOTEX CORP.APOTEX CORP.2023 second_quarter$120KJul 21, 2023
APOTEX CORP.APOTEX CORP.2023 first_quarter$140KApr 20, 2023